[go: up one dir, main page]

DK2086642T3 - Dnase til behandling af subfertilitet hos mænd - Google Patents

Dnase til behandling af subfertilitet hos mænd

Info

Publication number
DK2086642T3
DK2086642T3 DK07827224T DK07827224T DK2086642T3 DK 2086642 T3 DK2086642 T3 DK 2086642T3 DK 07827224 T DK07827224 T DK 07827224T DK 07827224 T DK07827224 T DK 07827224T DK 2086642 T3 DK2086642 T3 DK 2086642T3
Authority
DK
Denmark
Prior art keywords
subfertility
dnase
men
treatment
Prior art date
Application number
DK07827224T
Other languages
English (en)
Inventor
Benjamin Bartoov
Ronen Yehuda
Melamed Dobroslav
Original Assignee
Periness Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Periness Ltd filed Critical Periness Ltd
Application granted granted Critical
Publication of DK2086642T3 publication Critical patent/DK2086642T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
DK07827224T 2006-10-18 2007-10-18 Dnase til behandling af subfertilitet hos mænd DK2086642T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85240206P 2006-10-18 2006-10-18
PCT/IL2007/001250 WO2008047364A2 (en) 2006-10-18 2007-10-18 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility

Publications (1)

Publication Number Publication Date
DK2086642T3 true DK2086642T3 (da) 2014-09-29

Family

ID=39204993

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07827224T DK2086642T3 (da) 2006-10-18 2007-10-18 Dnase til behandling af subfertilitet hos mænd

Country Status (13)

Country Link
US (2) US20110033438A1 (da)
EP (3) EP2086642B1 (da)
JP (1) JP5323707B2 (da)
CN (2) CN105664141A (da)
AU (1) AU2007311444B2 (da)
BR (1) BRPI0717439A2 (da)
CA (1) CA2666794C (da)
DK (1) DK2086642T3 (da)
ES (1) ES2524458T3 (da)
PL (1) PL2086642T3 (da)
PT (1) PT2086642E (da)
RU (1) RU2009118359A (da)
WO (1) WO2008047364A2 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
ATE513557T1 (de) 2006-11-28 2011-07-15 Cls Therapeutics Ltd Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens
JP5092149B2 (ja) * 2008-05-30 2012-12-05 国立大学法人 千葉大学 精子機能の検査方法
WO2013114374A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US20150087610A1 (en) * 2012-03-20 2015-03-26 Monell Chemcial Senses Center Method of Modifying Fertility
CN104519906B (zh) * 2012-08-03 2016-10-05 辉凌公司 作为雌性不育的治疗靶标和诊断标记的无细胞dna
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
SG11201700485VA (en) * 2014-07-21 2017-02-27 Oxolife Sl Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques
CN107406837A (zh) 2015-01-04 2017-11-28 波塔力克斯有限公司 修饰的dna酶及其用途
US9304003B1 (en) * 2015-03-18 2016-04-05 Microsoft Technology Licensing, Llc Augmented reality navigation
JP6745873B2 (ja) 2015-05-22 2020-08-26 ドミトリエヴィッチ ゲンキン，ドミトリー 神経変性における治療標的としての細胞外ｄｎａ
KR101701618B1 (ko) 2015-06-23 2017-02-13 국립암센터 전도성 고분자를 이용한 세포 유리 ｄｎａ 검출용 구조체 및 이의 용도
CN105779568B (zh) * 2016-03-16 2019-09-24 四川大学华西第二医院 一种体外获能后精子质量评估的试剂盒及其使用方法
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
JP7577314B2 (ja) 2017-08-18 2024-11-05 ニュートロリス インコーポレイテッド 改変型ｄｎａｓｅ酵素及び治療における使用
EP3685165B1 (en) 2017-09-18 2022-04-20 Santersus AG Method and device for purification of blood from circulating cell free dna
WO2019143272A1 (en) 2018-01-16 2019-07-25 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity
AU2019358915A1 (en) 2018-10-08 2021-05-20 Neutrolis, Inc. Engineering of DNASE enzymes for manufacturing and therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
IL308581A (en) * 2021-05-24 2024-01-01 Peri Ness Tech Ltd Therapeutic regimen with dnase
US12053567B2 (en) 2021-12-27 2024-08-06 Santersus Ag Method and device for removal of circulating cell free DNA

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GB8517071D0 (en) * 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
US4996155A (en) * 1988-03-04 1991-02-26 Mycogen Corporation Bacillus thuringiensis gene encoding a coleopteran-active toxin
EP0853121B1 (en) * 1988-12-23 2007-03-28 Genentech, Inc. Human DNase
US20010008764A1 (en) * 1989-07-28 2001-07-19 Roy Ax Fertility-related proteins, and methods of use thereof
DE4024530A1 (de) * 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
US5484589A (en) * 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
US6251648B1 (en) * 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
GB9826541D0 (en) * 1998-12-02 1999-01-27 King S College London Modulation of sperm function
WO2001043540A2 (en) * 1999-12-17 2001-06-21 Oregon Health And Science University Methods for producing transgenic animals
CN1440298A (zh) * 2000-01-25 2003-09-03 气体药品技术公司 药用气雾剂
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6576634B1 (en) 2000-07-07 2003-06-10 N.V. Nutricia Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality
WO2002006444A2 (en) * 2000-07-14 2002-01-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Isolated polynucleotide sequences encoding a fertility associated antigen
NZ523656A (en) * 2000-08-31 2004-11-26 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
WO2003068254A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Glycosaminoglycan-dnase combination therapy
ATE494367T1 (de) * 2002-12-18 2011-01-15 Hoffmann La Roche Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität
DE60219809T2 (de) * 2002-12-18 2008-01-17 Coy, Johannes F., Dr. Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US20050120397A1 (en) * 2003-11-24 2005-06-02 Hermann Steller Compounds and methods for regulation of spermatid differentiation
JP4417273B2 (ja) * 2004-02-12 2010-02-17 独立行政法人科学技術振興機構 精子活性化剤および精子不活性化剤
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
WO2007131108A2 (en) * 2006-05-03 2007-11-15 Tmi Laboratories International, Inc. Method to diagnose and increase fertility of mammalian semen using dnase as diagnostic marker and therapeutic agent

Also Published As

Publication number Publication date
AU2007311444B2 (en) 2012-11-29
EP2416156A1 (en) 2012-02-08
CA2666794A1 (en) 2008-04-24
US20110033438A1 (en) 2011-02-10
US9149513B2 (en) 2015-10-06
WO2008047364A3 (en) 2008-08-28
EP2416155A1 (en) 2012-02-08
JP5323707B2 (ja) 2013-10-23
JP2010506903A (ja) 2010-03-04
CA2666794C (en) 2017-12-12
EP2416156B1 (en) 2015-12-30
ES2524458T3 (es) 2014-12-09
US20130121985A1 (en) 2013-05-16
AU2007311444A2 (en) 2009-05-28
EP2086642B1 (en) 2014-06-25
RU2009118359A (ru) 2010-11-20
AU2007311444A1 (en) 2008-04-24
WO2008047364A2 (en) 2008-04-24
CN101563134A (zh) 2009-10-21
PT2086642E (pt) 2014-09-30
BRPI0717439A2 (pt) 2013-11-19
PL2086642T3 (pl) 2015-02-27
CN105664141A (zh) 2016-06-15
EP2086642A2 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
DK2086642T3 (da) Dnase til behandling af subfertilitet hos mænd
DK2032598T3 (da) Axmi-031, axmi-039, axmi-040 og axmi-049, en familie af deltaendotoksingener og fremgangsmåder til deres anvendelse
DK2271642T3 (da) Pyridylinhibitorer af hedgehog signalering
DK2117523T3 (da) Inhibitorer af AKT-aktivitet
DK1986633T3 (da) Behandling af duchennes muskeldystrofi
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2848610T3 (da) Hæmmere af kinaseaktivitet
DK3208269T3 (da) Inhibitorer af c-fms-kinase
DK2086960T3 (da) Nye inhibitorer af glutaminylcyclase.
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
DK2097402T3 (da) Makrocykliske inhibitorer af hepatitis c-virus
DK1931350T3 (da) Administration af inhibitorer af dipeptidylpeptidase
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
DK2700786T3 (da) Modifikation af overførselspassage
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2019825T3 (da) Inhibitorer af human immundefektvirus-replikation
DK2015754T3 (da) Anvendelse af dpp-iv-inhibitorer
DK2091945T3 (da) Nye inhibitorer af glutaminylcyclase
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
CR10562A (es) Nuevos derivados de piridazina
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
EP2139883A4 (en) HIV-1 protease inhibitor